LVTX - Lava Therapeutics may be Squeezing

2024-02-29 14:24:12 ET

DENVER, Colo., Feb 29, 2024 ( 247marketnews.com )- After quietly trading sideways, today, Lava Therapeutics N.V. (NASDAQ: LVTX ) shot straight up from below $2.25 to a high of $3.41. It’s pulled back to $3.12, up $0.96 (+44.44%), 3.4M shares.

LVTX’s about section states, “LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody ® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering V?9V?2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. A Phase 1/2a dose escalation study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling in Europe and the United States ( NCT05369000 ). The Company is collaborating with Seagen for the clinical development of SGN-EGFRd2 (LAVA-1223) and Merck & Co., Inc., Rahway, NJ, USA for the clinical development of LAVA-1207. For more information, please visit www.lavatherapeutics.com , and follow us on LinkedIn , X , and YouTube .”

The post Lava Therapeutics may be Squeezing appeared first on 24/7 MarketNews .

For further details see: